CYAD 01 (Dartmouth College)

N/A

Report date: 2026/02/01 20:00:10

Base Information

Drug NameCYAD 01 (Dartmouth College)
Drug Alias NameCAR NKG2DNKR-2 T-cell immunotherapyNKR-T cellsNKR 2 T-cellCAR-T NKR-2 +[9] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNKG2D ligands
Therapy Area/IndicationsMyelodysplastic SyndromesColonic NeoplasmsColorectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDartmouth College
China Registration ClassN/A

Develop Information

Active CompaniesCelyad Oncology SA
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsMyelodysplastic SyndromesColonic NeoplasmsMultiple Myeloma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A